Regorafenib active in metastatic GI stromal tumors

May 23, 2012
Regorafenib active in metastatic GI stromal tumors

(HealthDay) -- Regorafenib, an inhibitor of multiple cancer-associated kinases, is active in patients with metastatic gastrointestinal stromal tumors (GIST) who have failed to respond to imatinib and sunitinib, according to a study published online May 21 in the Journal of Clinical Oncology.

Suzanne George, M.D., of the Dana-Farber Cancer Institute in Boston, and colleagues conducted a multicenter, single-stage phase II trial of oral regorafenib, 160 mg/day, in 34 patients with advanced GIST after failure of imatinib and sunitinib. The rate (CBR), defined as objective response (partial response and stable disease ≥16 weeks), was the primary study end point.

The researchers found that the CBR was 79 percent for the 33 patients who had received at least two cycles of regorafenib. Of these, 22 patients exhibited stable disease for 16 weeks or longer, and four patients achieved a partial response. Median progression-free survival (PFS) was 10 months. Hypertension and hand-foot-skin reaction were the most commonly observed grade 3 toxicities.

"In summary, regorafenib is a novel orally available multikinase inhibitor with notable activity in patients with advanced GIST after objective failure of both prior imatinib and sunitinib," the authors write. "The median PFS >10 months observed in these heavily pretreated patients supports the hypothesis that regorafenib may be a uniquely active agent in the management of GIST after treatment with imatinib and sunitinib."

Several authors disclosed financial ties to drug companies, including Bayer HealthCare Pharmaceuticals, which provided funding and the study drug.

Explore further: Drug improves survival of colorectal cancer patients, trial results show

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Tivozanib exhibits antitumor activity in renal cancer

April 10, 2012

(HealthDay) -- The potent, selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, tivozanib, demonstrates antitumor activity and is well tolerated in patients with advanced/metastatic renal cell carcinoma ...

ASCO: Dabrafenib/Trametinib active in metastatic melanoma

May 17, 2012

(HealthDay) -- For patients with V600 BRAF-mutant solid tumors, treatment with the oral BRAF inhibitor dabrafenib and the oral MEK 1/2 inhibitor trametinib is tolerated and has clinical activity in BRAF inhibitor-naive metastatic ...

Recommended for you

Combination therapy can prevent cytostatic resistance

November 26, 2015

Researchers at Karolinska Institutet have found a new way of preventing resistance to cytostatics used in the treatment of cancers such as medulloblastoma, the most common form of malignant brain tumour in children. The promising ...

Forecasting the path of breast cancer in a patient

November 23, 2015

USC researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting and surfing the Web.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.